Quarterly Revenue Growth
Consolidated revenue increased 29% year-over-year to $121.0 million in Q4 2025, driven primarily by Modern Oral growth ($41.3 million net revenue).
Adjusted EBITDA Improvement
Adjusted EBITDA rose 14% year-over-year to $30.0 million in the quarter, representing a 24.8% adjusted EBITDA margin.
Rapid Modern Oral (White Pouch) Expansion
Net white pouch sales increased 266% year-over-year (gross sales +337%); Modern Oral now represents 34% of consolidated net sales, up from 12% a year ago.
Stoker's Segment Strength
Stoker's segment net sales increased 70% year-over-year to $81.0 million; legacy Stoker's brands grew 9% to $39.7 million, and the segment now accounts for 67% of consolidated net sales.
Strong Balance Sheet and Cash Generation
Ended the quarter with $222.8 million of cash and generated $19.2 million of free cash flow in Q4; quarterly CapEx was $3.3 million.
2016 (FY2026) Modern Oral Guidance Introduced
Company initiated FY2026 Modern Oral guidance: gross sales $220 million to $240 million and net sales $180 million to $190 million; Q1 2026 adjusted EBITDA guide $24 million to $27 million.
Execution on Go-to-Market and Distribution
ALP (initially D2C) is entering bricks-and-mortar ahead of schedule with planned Q2 expansion; FRE distribution is expanding in large chains and independents; sales force expansion is ahead of schedule (goal to double sales force).
Manufacturing Progress
U.S. manufacturing build-out is progressing with initial production lines expected to be qualified at the new factory in coming months, expected to reduce future supply constraints and improve margins over time.